SCHEMBL3961997

SCHEMBL3961997

COCCOc1cc2c(cc1F)CC(=NO)C2=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
KIT P10721 2/20 0.32
SCN9A Q15858 1/20 0.32
PPARG P37231 1/20 0.32
DRD2 P14416 2/20 0.32
HTR2A P28223 2/20 0.32
SLC6A4 P31645 2/20 0.32
HTR1A P08908 1/20 0.32
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31
EGFR P00533 1/20 0.31
MAPK14 Q16539 1/20 0.30
FFAR1 O14842 1/20 0.30
ACHE P22303 1/20 0.30
TNFRSF1A P19438 1/20 0.30
TDP2 O95551 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3961991 1.00 ALDH1A1 (0.38) ALDH1A1CYP1A2CYP2C19KITSCN9A
SCHEMBL3974070 0.90 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C19PPARG
SCHEMBL3974062 0.90 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C19PPARG
SCHEMBL3967834 0.86 PPARG (0.41) ALDH1A1CYP1A2CYP2C19PPARG
SCHEMBL3967838 0.86 PPARG (0.41) ALDH1A1CYP1A2CYP2C19PPARG
SCHEMBL3972963 0.79 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C19MAPK14ACHE
SCHEMBL3972966 0.79 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C19MAPK14ACHE
SCHEMBL13715629 0.79 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C19MAPK14ACHE
SCHEMBL16548381 0.76 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C19PPARGHTR2A
SCHEMBL1877045 0.76 ALDH1A1 (0.53) ALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 ALDH1A1 198/4885CYP1A2 9/4885CYP2C19 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.